Overview

Study of Multiple Doses of Danicopan in Healthy Participants

Status:
Completed
Trial end date:
2017-01-11
Target enrollment:
Participant gender:
Summary
This was a multiple ascending dose, randomized, double-blind study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of danicopan in healthy participants. Four different doses (75 milligrams [mg], 200 mg, 500 mg, 800 mg) and dose-matched placebo were administered under fasted conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Alexion Pharmaceuticals
Collaborator:
Achillion, a wholly owned subsidiary of Alexion